Research prototype, not medical advice.

01 — Genomic instability

Primary hallmark ("damage") according to López-Otín et al., Cell 2023 (doi:10.1016/j.cell.2022.11.001).

1. Definition

Accumulation, over a lifetime, of lesions and alterations of nuclear and mitochondrial DNA (breaks, point mutations, rearrangements, aneuploidies, retrotransposon insertions) that exceed the repair capacities of the cell. It meets the three criteria of a hallmark: it increases with age, its experimental aggravation accelerates aging, and its reduction slows it down, at least in animals (López-Otín 2013, doi:10.1016/j.cell.2013.05.039; Schumacher 2021, doi:10.1038/s41586-021-03307-7).

In plain terms: DNA is the "instruction manual" of every cell. It is damaged tens of thousands of times a day; the cell repairs almost everything, but not everything. Uncorrected errors accumulate, like typos that add up each time a manual is copied.

2. Mechanisms and sources

Sources of damage.

Nature of the accumulated alterations.

Cellular consequences. Unrepaired damage leads to (i) a transmitted mutation, (ii) cell-cycle arrest and senescence, (iii) cell death, or (iv) clonal selection. The persistent DNA damage response (DDR) is a major driver of senescence and inflammation (Schumacher 2021).

3. Symptoms and clinical manifestations

Human progeroid syndromes (monogenic accelerated aging) — the most direct evidence in humans:

Clonal hematopoiesis of indeterminate potential (CHIP): blood clones carrying mutations (DNMT3A, TET2, ASXL1…) expand in >10 % of people over 70. They increase the risk of blood cancer, overall mortality (Jaiswal 2014, doi:10.1056/NEJMoa1408617) and cardiovascular risk (Jaiswal 2017, doi:10.1056/NEJMoa1701719); in mice, Tet2-deficient macrophages accelerate atherosclerosis through inflammation (IL-1β/NLRP3) (Fuster 2017, doi:10.1126/science.aag1381).

GWAS: age at menopause, a marker of ovarian aging, is strongly associated with variants in DNA repair genes; manipulating them in mice changes the ovarian reserve (Ruth 2021, doi:10.1038/s41586-021-03779-7).

Associated age-related diseases: cancers (the main one), cardiovascular diseases (CHIP, LOY), neurodegeneration (neuronal mutations), ovarian failure, immunosenescence.

4. Interactions with the other hallmarks

Hallmark (2023 numbering)Link with genomic instability
2. Telomere attritionTelomeres are a specialised form of DNA damage that is hard to repair; persistent DDR at telomeres (see file 02).
3. Epigenetic alterationsBreak repair redistributes chromatin proteins and erodes epigenetic information (Yang 2023, doi:10.1016/j.cell.2022.12.027); loss of heterochromatin → awakening of LINE-1.
4. Loss of proteostasisMutations produce misfolded proteins; some repair proteins depend on chaperones.
6. Deregulated nutrient sensingDamage represses the GH/IGF-1 axis (survival response) (Niedernhofer 2006); repair consumes NAD+ (PARP) at the expense of sirtuins (Covarrubias 2021, doi:10.1038/s41580-020-00313-x).
7. Mitochondrial dysfunctionmtDNA mutations → failing respiratory chain → more free radicals → more damage (debated vicious circle).
8. Cellular senescencePersistent DDR is the main trigger of senescence.
9. Stem cell exhaustionDamage exhausts stem cells or favours their clonal drift (CHIP).
10. Altered intercellular communicationThe secretome of damaged/senescent cells alters neighbouring tissues.
11. Chronic inflammationCytoplasmic DNA (LINE-1, micronuclei) → cGAS-STING pathway → interferons (De Cecco 2019); CHIP → IL-1β.
12. DysbiosisSome bacteria produce genotoxins: colibactin from pks+ E. coli leaves a distinct mutational signature in organoids and in human colorectal cancers (Pleguezuelos-Manzano 2020, doi:10.1038/s41586-020-2080-8). The link with normal aging remains indirect.

5. Existing or investigational remedies

InterventionTargetLevel of evidenceKey resultSource
LonafarnibInhibits farnesylation of progerin (HGPS)Approved (FDA 2020, progeria)Reduced mortality in treated vs untreated children (cohort study)Gordon 2018, doi:10.1001/jama.2018.3264
Base editing (ABE) of the LMNA mutationDNA correctionPreclinical (mice)A single injection corrects the mutation, reduces progerin and doubles median survivalKoblan 2021, doi:10.1038/s41586-020-03086-7
NAD+ precursors (NMN, NR)Restore NAD+ (PARP, sirtuins, repair)Solid preclinical; human phase 1-2 trialsMice: lessening of age-related declines (Mills 2016); humans: NR safe and raises NAD+ (Martens 2018); NMN improves muscle insulin sensitivity in prediabetic women (Yoshino 2021). No demonstrated benefit on DNA repair in humans.doi:10.1016/j.cmet.2016.09.013; doi:10.1038/s41467-018-03421-7; doi:10.1126/science.abe9985
SIRT6 activationDouble-strand break repairPreclinical (transgenic mice)Overexpression: increased longevity in male miceKanfi 2012
BubR1 overexpressionChromosome segregationPreclinical (mice)Less aneuploidy and fewer cancers, longer lifeBaker 2012
Reverse transcriptase inhibitors (e.g. lamivudine)Block LINE-1PreclinicalReduced interferon-type inflammation in old miceDe Cecco 2019
Prevention of exposure (UV, tobacco)Reduce exogenous damageEstablished (epidemiology)Fewer skin and lung cancersconsensus, not specific to aging
Targeting CHIP clones / IL-1βCHIP-related inflammationHypothesis; secondary analyses of trialsExploratory analysis of the CANTOS trial: in carriers of TET2 CHIP, canakinumab (anti-IL-1β) reduces cardiovascular events (HR 0.38; 95 % CI 0.15-0.96), non-significant interactionSvensson 2022, doi:10.1001/jamacardio.2022.0386

Finding: no intervention has been shown in humans to slow the accumulation of somatic mutations. The only clinical successes concern monogenic diseases (progeria).

6. Open questions

  1. Causality in normal aging: are somatic mutations numerous enough to explain functional decline, or mainly a cancer risk? The mutations/species-longevity parallel (Cagan 2022) does not prove causality.
  2. Damage vs mutation: is it the persistent lesion (DDR signal, senescence) or the fixed mutation that matters most? Schumacher 2021 leans towards lesions.
  3. mtDNA: do mutations reach a functional threshold in normal human aging?
  4. Clonal mosaicism (CHIP, LOY, clones in the oesophagus or skin): causal factor of disease or mere marker? Should it be treated?
  5. Improving repair without favouring the survival of cancer cells: no validated strategy in humans.
  6. Biomarkers: how can the damage burden be measured routinely (single-molecule sequencing, LOY, CHIP)?

7. References

  1. López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell 2023. doi:10.1016/j.cell.2022.11.001
  2. López-Otín C, et al. The hallmarks of aging. Cell 2013. doi:10.1016/j.cell.2013.05.039
  3. Schumacher B, et al. The central role of DNA damage in the ageing process. Nature 2021. doi:10.1038/s41586-021-03307-7
  4. Martincorena I, et al. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015. doi:10.1126/science.aaa6806
  5. Abascal F, et al. Somatic mutation landscapes at single-molecule resolution. Nature 2021. doi:10.1038/s41586-021-03477-4
  6. Lodato MA, et al. Aging and neurodegeneration are associated with increased mutations in single human neurons. Science 2018. doi:10.1126/science.aao4426
  7. Cagan A, et al. Somatic mutation rates scale with lifespan across mammals. Nature 2022. doi:10.1038/s41586-022-04618-z
  8. Tian X, et al. SIRT6 is responsible for more efficient DNA double-strand break repair in long-lived species. Cell 2019. doi:10.1016/j.cell.2019.03.043
  9. Kanfi Y, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012. doi:10.1038/nature10815
  10. Forsberg LA, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet 2014. doi:10.1038/ng.2966
  11. Sano S, et al. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. Science 2022. doi:10.1126/science.abn3100
  12. Baker DJ, et al. BubR1 insufficiency causes early onset of aging-associated phenotypes. Nat Genet 2004. doi:10.1038/ng1382
  13. Baker DJ, et al. Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan. Nat Cell Biol 2012. doi:10.1038/ncb2643
  14. De Cecco M, et al. L1 drives IFN in senescent cells and promotes age-associated inflammation. Nature 2019. doi:10.1038/s41586-018-0784-9
  15. Simon M, et al. LINE1 derepression in aged wild-type and SIRT6-deficient mice drives inflammation. Cell Metab 2019. doi:10.1016/j.cmet.2019.02.014
  16. Trifunovic A, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004. doi:10.1038/nature02517
  17. Kujoth GC, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005. doi:10.1126/science.1112125
  18. Kauppila TES, et al. Mammalian mitochondria and aging: an update. Cell Metab 2017. doi:10.1016/j.cmet.2016.09.017
  19. Eriksson M, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003. doi:10.1038/nature01629
  20. Yu CE, et al. Positional cloning of the Werner's syndrome gene. Science 1996. doi:10.1126/science.272.5259.258
  21. Niedernhofer LJ, et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 2006. doi:10.1038/nature05456
  22. Yousefzadeh MJ, et al. An aged immune system drives senescence and ageing of solid organs. Nature 2021. doi:10.1038/s41586-021-03547-7
  23. Jaiswal S, et al. Age-related clonal hematopoiesis associated with adverse outcomes. NEJM 2014. doi:10.1056/NEJMoa1408617
  24. Jaiswal S, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. NEJM 2017. doi:10.1056/NEJMoa1701719
  25. Fuster JJ, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017. doi:10.1126/science.aag1381
  26. Ruth KS, et al. Genetic insights into biological mechanisms governing human ovarian ageing. Nature 2021. doi:10.1038/s41586-021-03779-7
  27. Yang JH, et al. Loss of epigenetic information as a cause of mammalian aging. Cell 2023. doi:10.1016/j.cell.2022.12.027
  28. Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol 2021. doi:10.1038/s41580-020-00313-x
  29. Gordon LB, et al. Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome. JAMA 2018. doi:10.1001/jama.2018.3264
  30. Koblan LW, et al. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature 2021. doi:10.1038/s41586-020-03086-7
  31. Mills KF, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab 2016. doi:10.1016/j.cmet.2016.09.013
  32. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018. doi:10.1038/s41467-018-03421-7
  33. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021. doi:10.1126/science.abe9985
  34. Pleguezuelos-Manzano C, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature 2020. doi:10.1038/s41586-020-2080-8
  35. Svensson EC, et al. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol 2022. doi:10.1001/jamacardio.2022.0386

DOIs verified via the Crossref API on 2026-10-19.